Cryoport, Inc. Files Definitive Proxy Statement for 2024 Meeting

TL;DR

<b>Cryoport, Inc. has filed its 2024 Definitive Proxy Statement, outlining corporate governance and shareholder matters for the upcoming meeting.</b>

AI Summary

Cryoport, Inc. (CYRX) filed a Proxy Statement (DEF 14A) with the SEC on April 3, 2024. Cryoport, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 3, 2024. The filing pertains to the company's 2024 Proxy Statement, with a reporting period ending May 17, 2024. The company's fiscal year ends on December 31. Cryoport, Inc. is incorporated in Nevada (NV). The company operates in the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking Cryoport, Inc., this filing contains several important signals. This filing provides shareholders with essential information regarding the company's leadership, executive compensation, and voting matters, enabling informed participation in corporate decisions. As a company in the Cell & Gene therapy supply chain, this proxy statement is crucial for understanding Cryoport's strategic direction and governance in a rapidly evolving industry.

Risk Assessment

Risk Level: low — Cryoport, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate disclosure rather than immediate financial or operational news.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to assess management's alignment with shareholder interests.

Key Numbers

• 2024-04-03 — Filing Date (Date the DEF 14A was filed)
• 2024-05-17 — Reporting Period End Date (Conformed period of report)
• 1231 — Fiscal Year End (Company's fiscal year end)
• 001-34632 — SEC File Number (SEC file number for Cryoport, Inc.)

Key Players & Entities

• Cryoport, Inc. (company) — Registrant name
• 2024 (date) — Proxy Statement year
• 2024-04-03 (date) — Filing date
• 2024-05-17 (date) — Reporting period end date
• 1934 Act (regulator) — SEC Act
• NV (jurisdiction) — State of Incorporation
• 2834 (industry) — Standard Industrial Classification
• 112 Westwood Place, Suite 350 (address) — Business address

FAQ

Risk Factors

• Challenging Macroeconomic and Geopolitical Environments [medium — market]: The company experienced significant hurdles in 2023 due to a challenging global landscape, including a drop in demand for cryogenic systems, particularly in China.
• Slower than Anticipated Market Development [medium — market]: The market development of commercial Cell & Gene therapies has not occurred as rapidly as anticipated, impacting the company's growth trajectory.

Key Dates

• 2024-04-03: Filing of Definitive Proxy Statement — Provides shareholders with information for the upcoming 2024 annual meeting.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This filing provides detailed information about the company's annual meeting, including voting matters, executive compensation, and board nominations.)

Cell & Gene Therapy

Therapies that use genes or cells to treat diseases. (Cryoport operates within the supply chain for these advanced therapies, making market developments critical to its business.)

Key Financial Figures

• $500,000 — We finished that year at approximately $500,000 in revenue. Today, we concluded 2023 wi
• $230 million — nue. Today, we concluded 2023 with over $230 million in revenue, over $450 million of cash a
• $450 million — with over $230 million in revenue, over $450 million of cash and short-term investments, and
• $0.001 — holders of our common stock, par value $0.001 per share, and the record holders of ou
• $11,000 — es on our behalf. We have agreed to pay $11,000, plus reasonable and approved out-of-po

Filing Documents

• ny20018457x1_def14a.htm (DEF 14A) — 2218KB
• edge20001940x1_chair.jpg (GRAPHIC) — 5KB
• edge20001940x1_member.jpg (GRAPHIC) — 4KB
• logo_cryoport24.jpg (GRAPHIC) — 39KB
• logo_cryoportcircle24.jpg (GRAPHIC) — 26KB
• logo_cryoportcover24.jpg (GRAPHIC) — 358KB
• ny20018457x1_degreex1.jpg (GRAPHIC) — 5KB
• ny20018457x1_dhancock.jpg (GRAPHIC) — 88KB
• ny20018457x1_jshelton.jpg (GRAPHIC) — 80KB
• ny20018457x1_lbaddour.jpg (GRAPHIC) — 54KB
• ny20018457x1_matrix.jpg (GRAPHIC) — 164KB
• ny20018457x1_piechart07a.jpg (GRAPHIC) — 127KB
• ny20018457x1_piechart08x1.jpg (GRAPHIC) — 59KB
• ny20018457x1_rberman.jpg (GRAPHIC) — 86KB
• ny20018457x1_rhariri.jpg (GRAPHIC) — 65KB
• ny20018457x1_rjagannath.jpg (GRAPHIC) — 80KB
• ny20018457x1_rmandalam.jpg (GRAPHIC) — 66KB
• ny20018457x1_table01a.jpg (GRAPHIC) — 458KB
• ny20018457x1_table02a.jpg (GRAPHIC) — 207KB
• ny20018457x1_table03a.jpg (GRAPHIC) — 264KB
• ny20018457x1_table04a.jpg (GRAPHIC) — 232KB
• ny20018457x1_pc01.jpg (GRAPHIC) — 634KB
• ny20018457x1_pc02.jpg (GRAPHIC) — 461KB
• ny20018457x1_pvpchart01x2.jpg (GRAPHIC) — 172KB
• ny20018457x1_pvpchart02x2.jpg (GRAPHIC) — 160KB
• ny20018457x1_pvpchart03x2.jpg (GRAPHIC) — 155KB
• 0001140361-24-017597.txt (&nbsp;) — 13902KB
• cyrx-20240517.xsd (EX-101.SCH) — 6KB
• cyrx-20240517_def.xml (EX-101.DEF) — 6KB
• cyrx-20240517_lab.xml (EX-101.LAB) — 12KB
• cyrx-20240517_pre.xml (EX-101.PRE) — 5KB
• ny20018457x1_def14a_htm.xml (XML) — 408KB

Forward-Looking Statements

Forward-Looking Statements 11 Proposal 1 Election of Directors 21 Corporate Governance and Board Matters 42 45 Proposal 2 To ratify the appointment of Deloitte & Touche LLP 46 Independent Registered Public Accounting Firm Fees 49 Audit Committee Report 50 Proposal 3 To approve, on an advisory basis, the compensation of the named executive officers 52 Proposal 4 To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares for issuance thereunder 63 Compensation Discussion and Analysis 79 Compensation Committee Report 80

Executive Compensation

Executive Compensation 97 Director Compensation 99 Equity Compensation Plan Information 100 Certain Relationships and Related Transactions 102 Delinquent Section 16(a) Reports 103 Stockholder Proposals for Next Annual Meeting 104 Other Matters Cryoport Inc i 2024 Proxy Statement TABLE OF CONTENTS General Information INTRODUCTION Cryoport, Inc., a Nevada corporation (referred to as "we," "us," "our," "Company" or "Cryoport"), is furnishing this proxy statement (this "Proxy Statement") to you in connection with the Company's solicitation of proxies on behalf of the board of directors (the "Board" or "Board of Directors") of the Company with respect to the 2024 Annual Meeting of Stockholders of the Company and any adjournment thereof (the "Annual Meeting") to be held as a virtual meeting via live webcast on the Internet on Friday, May 17, 2024, at 10:00 a.m. CDT. There will not be a physical meeting location and stockholders will not be able to attend the Annual Meeting in person. On or about April 3, 2024, we began mailing a Notice of Internet Availability of Proxy Materials (the "Notice") to the record holders of our common stock, par value $0.001 per share, and the record holders of our Series C Convertible Preferred Stock, par value $0.001 per share ("Series C Preferred Stock"). This Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report") are available at www.proxyvote.com. Throughout this Proxy Statement, holders of our common stock and our Series C Preferred Stock are referred to collectively as "stockholders." Holders of our common stock and our Series C Preferred Stock will vote together as a single class on all matters at the Annual Meeting. Cryoport Inc 2024 Proxy Statement TABLE OF CONTENTS Frequently Asked Questions WHAT IS THE PURPOSE OF THE ANNUAL MEETING? The purpose of the Annual Meeting is to vote on the following matters: 1. To elect seven directors;

View Full Filing

View this DEF 14A filing on SEC EDGAR